Targeted MRI Contrast Agent for Breast Cancer Shows Promising Results

Researchers at the Iran University of Medical Sciences have made a breakthrough in the development of a targeted magnetic resonance imaging (MRI) contrast agent for breast cancer. By conjugating ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles with the FROP-1 peptide, the team created a novel agent that specifically targets breast cancer cells. This innovation has the potential to improve the accuracy and effectiveness of MRI scans for diagnosing and monitoring breast cancer.

Key Takeaways:

• The researchers synthesized USPIO nanoparticles with an average size of 3.78 ± 0.2 nm using the co-precipitation method.
• The nanoparticles were conjugated with the FROP-1 peptide using 1-ethyl-3-(3-dimethylaminopropyl) carbide diamide hydrochloride (EDC) to form a targeted contrast agent.
• The FeO@FROP-1 nanoparticles showed good biocompatibility and had high r1 relaxivity and r2/r1 ratios of 2.608 mMS and 1.18, respectively.
• The nanoparticles demonstrated specific targeting effects on breast cancer cells, as shown by cellular uptake and cell MR imaging.
• The contrast intensity of the FeO@FROP-1 nanoprobe increased with increasing Fe concentration, indicating its potential for imaging applications.
• The synthesized nanoparticles had better imaging performance than the commercial contrast agent Dotarem (gadoterate meglumine).

Statistics:

• The average size of the FeO nanoparticles was 3.78 ± 0.2 nm.
• The r1 relaxivity of the FeO@FROP-1 nanoparticles was 2.608 mMS.
• The r2/r1 ratio of the FeO@FROP-1 nanoparticles was 1.18.
• The contrast intensity of the FeO@FROP-1 nanoprobe increased by 20% with a 10-fold increase in Fe concentration.

Sources:

• FROP-1 peptide-conjugated ultrasmall superparamagnetic nanoparticles as a targeted T1-weighted MR contrast agent for breast cancer: in vitro study. BMC Biomedical Engineering, 2025;7(1):5.
• Iran University of Medical Sciences Reports Findings in Breast Cancer (FROP-1 peptide-conjugated ultrasmall superparamagnetic nanoparticles as a targeted T1-weighted MR contrast agent for breast cancer: in vitro study). Nanotechnology Weekly. May 12, 2025; p 528.